| Year |
Citation |
Score |
| 2022 |
Baytas O, Kauer JA, Morrow EM. Loss of mitochondrial enzyme GPT2 causes early neurodegeneration in locus coeruleus. Neurobiology of Disease. 105831. PMID 35908744 DOI: 10.1016/j.nbd.2022.105831 |
0.57 |
|
| 2021 |
Baytas O, Davidson SM, DeBerardinis RJ, Morrow EM. Mitochondrial enzyme GPT2 regulates metabolic mechanisms required for neuron growth and motor function in vivo. Human Molecular Genetics. PMID 34519342 DOI: 10.1093/hmg/ddab269 |
0.562 |
|
| 2019 |
Ouyang Q, Kavanaugh BC, Joesch-Cohen L, Dubois B, Wu Q, Schmidt M, Baytas O, Pastore SF, Harripaul R, Mishra S, Hussain A, Kim KH, Holler-Managan YF, Ayub M, Mir A, et al. GPT2 mutations in autosomal recessive developmental disability: extending the clinical phenotype and population prevalence estimates. Human Genetics. PMID 31471722 DOI: 10.1007/S00439-019-02057-X |
0.603 |
|
| 2019 |
Kavanaugh BC, Warren EB, Baytas O, Schmidt M, Merck D, Buch K, Liu JS, Phornphutkul C, Caruso P, Morrow EM. Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification. American Journal of Medical Genetics. Part A. PMID 31403263 DOI: 10.1002/Ajmg.A.61322 |
0.597 |
|
| 2018 |
Baytaş O, Morrow EM. The Role of Mitochondrial Glutamate Metabolism in Cognitive Development and Disease. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 43: 229-230. PMID 29192671 DOI: 10.1038/Npp.2017.202 |
0.538 |
|
| 2016 |
Ouyang Q, Nakayama T, Baytas O, Davidson SM, Yang C, Schmidt M, Lizarraga SB, Mishra S, Ei-Quessny M, Niaz S, Gul Butt M, Imran Murtaza S, Javed A, Chaudhry HR, Vaughan DJ, et al. Mutations in mitochondrial enzyme GPT2 cause metabolic dysfunction and neurological disease with developmental and progressive features. Proceedings of the National Academy of Sciences of the United States of America. PMID 27601654 DOI: 10.1073/Pnas.1609221113 |
0.609 |
|
| Show low-probability matches. |